

Global Scleroderma Diagnostics and Therapeutics Market Size study, by Drug Class (Immunosuppressors, ERA, CCBs, PA), by Indication (Systemic, Localized), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G185622B54FEEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G185622B54FEEN

Abstracts

The Global Scleroderma Diagnostics and Therapeutics Market is valued at approximately USD 2.41 billion in 2023 and is projected to expand at a steady compound annual growth rate (CAGR) of more than 5.00% during the forecast period from 2024 to 2032. Scleroderma, a chronic autoimmune disorder marked by progressive fibrosis and vascular abnormalities, continues to impose a significant burden on healthcare systems globally. As medical researchers and pharmaceutical developers unravel the complex immunological and pathological pathways underpinning the disease, the demand for innovative diagnostic tools and efficacious treatment regimens has surged. The market is witnessing a paradigm shift driven by a surge in biologic therapeutics, precision medicine, and advancements in early-stage diagnostics that enhance patient outcomes by enabling tailored treatment strategies.

This growth trajectory is catalyzed by increasing disease prevalence, growing awareness among clinicians and patients, and sustained investments into autoimmune and rare disease research. Government initiatives and orphan drug designations have incentivized pharmaceutical companies to invest in novel therapeutics targeting scleroderma's multifactorial manifestations. Furthermore, with a rising aging population globally, who are more susceptible to autoimmune conditions, the demand for robust diagnostics and long-term therapeutic interventions is poised to intensify. However, the market remains constrained by limited patient accessibility to high-cost biologics, variability in disease presentation, and the absence of curative treatments, which together pose significant challenges in patient management and therapeutic

development.

Breakthrough innovations in immunosuppressive drug classes and vasodilatory agents, such as endothelin receptor antagonists (ERAs) and calcium channel blockers (CCBs), are reshaping the treatment landscape. These classes have shown promise in attenuating disease progression and improving quality of life, particularly in systemic manifestations. In addition, emerging therapies aimed at targeting fibrotic pathways are under clinical evaluation, signaling a new frontier in scleroderma management. Complementing this trend is the integration of AI-driven diagnostic algorithms and biomarker-based screening, which are streamlining diagnosis, a process historically hindered by non-specific symptomatology and late-stage identification.

Regionally, the North American market commands a substantial share due to robust healthcare infrastructure, high awareness levels, and significant R&D investments in rare and autoimmune diseases. The United States, in particular, exhibits strong adoption of biologic therapies and a favorable regulatory landscape for orphan drugs. Europe follows closely, benefiting from strategic collaborations among academic institutions and pharmaceutical firms, as well as government-backed initiatives for early diagnostics. Meanwhile, the Asia Pacific region is expected to witness the fastest growth over the forecast period, fueled by expanding healthcare access, growing incidence of autoimmune diseases, and increasing clinical trials in emerging economies such as China and India. Latin America and the Middle East & Africa, while exhibiting modest growth, are gradually adopting advanced diagnostics and therapeutic protocols through global health partnerships and technology transfer programs.

Major market player included in this report are:

Actelion Pharmaceuticals Ltd

Boehringer Ingelheim International GmbH

Pfizer Inc.

Bristol-Myers Squibb Company

Bayer AG

Sanofi S.A.

F. Hoffmann-La Roche AG

Novartis AG

AbbVie Inc.

Johnson & Johnson

Merck & Co., Inc.

Medtronic plc

GlaxoSmithKline plc

AstraZeneca PLC

Teva Pharmaceutical Industries Ltd

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Immunosuppressors

ERA (Endothelin Receptor Antagonists)

CCBs (Calcium Channel Blockers)

PA (Prostacyclin Analogues)

By Indication

Systemic

Localized

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Actelion Pharmaceuticals Ltd

Boehringer Ingelheim International GmbH

Pfizer Inc.

Bristol-Myers Squibb Company

Bayer AG

Sanofi S.A.

F. Hoffmann-La Roche AG

Novartis AG

AbbVie Inc.

Johnson & Johnson

Merck & Co., Inc.

Medtronic plc

GlaxoSmithKline plc

AstraZeneca PLC

Teva Pharmaceutical Industries Ltd

Contents

CHAPTER 1. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET EXECUTIVE SUMMARY

- 1.1. Global Scleroderma Diagnostics and Therapeutics Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Class
 - 1.3.2. By Indication
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Disease Prevalence & Awareness
 - 2.3.4.2. Technological Advancements (AI & Biomarkers)
 - 2.3.4.3. Reimbursement Landscape
 - 2.3.4.4. Patient Access & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS

Global Scleroderma Diagnostics and Therapeutics Market Size study, by Drug Class (Immunosuppressors, ERA, CCBs...

MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Global Disease Prevalence and Aging Population
- 3.1.2. Surge in Biologic and Precision Therapeutics
- 3.1.3. Advancements in Early-Stage AI-Driven Diagnostics

3.2. Market Challenges

- 3.2.1. High Cost and Limited Accessibility of Biologics
- 3.2.2. Heterogeneous Disease Presentation and Diagnosis Delay
- 3.2.3. Lack of Curative Treatment Options

3.3. Market Opportunities

- 3.3.1. Emerging Anti-Fibrotic and Vasodilatory Agents
- 3.3.2. Orphan Drug Incentives and Government Initiatives
- 3.3.3. Expansion in Asia Pacific and Emerging Economies

CHAPTER 4. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces
- 4.1.7. Porter's Five Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET SIZE & FORECASTS BY DRUG CLASS 2022–2032

5.1. Segment Dashboard

5.2. Global Market: Immunosuppressors Revenue Trend Analysis, 2022 & 2032 (USD Million)

5.3. Global Market: Endothelin Receptor Antagonists (ERA) Revenue Trend Analysis, 2022 & 2032 (USD Million)

5.4. Global Market: Calcium Channel Blockers (CCBs) Revenue Trend Analysis, 2022 & 2032 (USD Million)

5.5. Global Market: Prostacyclin Analogues (PA) Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 6. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022–2032

6.1. Segment Dashboard

6.2. Global Market: Systemic Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)

6.3. Global Market: Localized Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 7. GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022–2032

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. By Drug Class breakdown size & forecasts, 2022–2032

7.1.1.2. By Indication breakdown size & forecasts, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. U.K. Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

7.3.1. China Market

- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Actelion Pharmaceuticals Ltd
 - 8.1.2. Boehringer Ingelheim International GmbH
 - 8.1.3. Pfizer Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Actelion Pharmaceuticals Ltd
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Boehringer Ingelheim International GmbH
 - 8.3.3. Pfizer Inc.
 - 8.3.4. Bristol-Myers Squibb Company
 - 8.3.5. Bayer AG
 - 8.3.6. Sanofi S.A.
 - 8.3.7. F. Hoffmann-La Roche AG
 - 8.3.8. Novartis AG
 - 8.3.9. AbbVie Inc.
 - 8.3.10. Johnson & Johnson
 - 8.3.11. Merck & Co., Inc.
 - 8.3.12. Medtronic plc

8.3.13. GlaxoSmithKline plc

8.3.14. AstraZeneca PLC

8.3.15. Teva Pharmaceutical Industries Ltd

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

List Of Tables

LIST OF TABLES

TABLE 1. Global Scleroderma Diagnostics and Therapeutics market, report scope
TABLE 2. Global market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Global market estimates & forecasts by Drug Class 2022–2032 (USD Million)
TABLE 4. Global market estimates & forecasts by Indication 2022–2032 (USD Million)
TABLE 5. Global market by segment, estimates & forecasts, 2022–2032 (USD Million)
TABLE 6. Global market by region, estimates & forecasts, 2022–2032 (USD Million)
TABLE 7. U.S. market estimates & forecasts, 2022–2032 (USD Million)
TABLE 8. U.S. market estimates & forecasts by segment, 2022–2032 (USD Million)
TABLE 9. Canada market estimates & forecasts, 2022–2032 (USD Million)
TABLE 10. Canada market estimates & forecasts by segment, 2022–2032 (USD Million)
... (Report contains 100+ tables; list to be updated in final deliverable)

List Of Figures

LIST OF FIGURES

- FIG 1. Global Scleroderma market, research methodology
- FIG 2. Global market, estimation techniques
- FIG 3. Global market size estimates & forecast methods
- FIG 4. Global Scleroderma market, key trends 2023
- FIG 5. Global market, growth prospects 2022–2032
- FIG 6. Global market, Porter's Five Forces model
- FIG 7. Global market, PESTEL analysis
- FIG 8. Global market, value chain analysis
- FIG 9. Global market by segment, 2022 & 2032 (USD Million)
- FIG 10. Global market by segment, 2022 & 2032 (USD Million)
- FIG 11. Global market by segment, 2022 & 2032 (USD Million)
- FIG 12. Global market by segment, 2022 & 2032 (USD Million)
- FIG 13. Global market, regional snapshot 2022 & 2032
- FIG 14. North America market, 2022 & 2032 (USD Million)
- FIG 15. Europe market, 2022 & 2032 (USD Million)
- FIG 16. Asia Pacific market, 2022 & 2032 (USD Million)
- FIG 17. Latin America market, 2022 & 2032 (USD Million)
- FIG 18. Middle East & Africa market, 2022 & 2032 (USD Million)
- FIG 19. Global market, company market share analysis (2023)
- ... (Report contains 50+ figures; list to be updated in final deliverable)

I would like to order

Product name: Global Scleroderma Diagnostics and Therapeutics Market Size study, by Drug Class (Immunosuppressors, ERA, CCBs, PA), by Indication (Systemic, Localized), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G185622B54FEEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G185622B54FEEN.html>